The Meaningful Function of the Emerging Clinical Targets-lncRNA MEG3 in Gastric Cancer

Title:The Meaningful Function of the Emerging Clinical Targets-lncRNA MEG3 in Gastric Cancer

Volume: 29 Issue: 28

Author(s): Yi Zhang, Yingchi Wang, Yutong Jiang, Huahui Bai and Yu Wen*

Affiliation:

• Clinical Medical College, China Medical University, Shenyang 110000, China

Abstract: LncRNA MEG3, a tumor suppressor gene, is related to reducing the proliferation, migration, and invasion as well as apoptosis abilities of gastric cancer (GC), which is a promising therapeutic target in patients. We conducted a comprehensive search of the literature on Pubmed using the keywords “lncRNA MEG3 and gas cancer” from 2014 to the present. Here, we provide a systematic and comprehensive summary of existing knowledge of the lncRNAs MEG3 and reveal its biological function and specific mechanisms in gastric cancer. MEG3 is involved in many molecular mechanisms that inhibit the development and progression of gastric cancer. For example, MEG3 can inhibit the proliferation of gastric cancer cells by inhibiting the expression of miR-21, miR-665, miR-148, miR-208, etc. MEG3 inhibits gastric carcinogenesis by inhibiting the negative regulator MDM2, regulating the expression of tumor suppressor genes p53 and Rb gene, and managing PI3K/Akt and Wnt/β-catenin signaling pathways. Additionally, gastric cancer patients with low MEG3 expression have poor prognosis, and transfection of MEG3 can improve the overall survival time of normal cells. Eventually, lncRNA MEG3 can be used as a biomarker or target for intervention, thereby providing new insights for gastric cancer therapy.

Cite this article as:

Zhang Yi, Wang Yingchi, Jiang Yutong, Bai Huahui and Wen Yu*, The Meaningful Function of the Emerging Clinical Targets-lncRNA MEG3 in Gastric Cancer, Current Pharmaceutical Design 2023; 29 (28) . https://dx.doi.org/10.2174/0113816128254674230925040033